Amgen’s biosimilar adalimumab (ABP 501), a biosimilar of AbbVie’s Humira, has received a positive opinion regarding marketing from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
The active ingredient of ABP 501 is an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that has the same amino acid sequence as adalimumab. The decision is the first time an adalimumab biosimilar has been recommended for approval in the European Union (EU). ABP 501, branded as Amjevita (adalimumab-atto) in the United States, was approved by the FDA in September 2016. However, Amjevita has not yet been marketed in the US because AbbVie sued Amgen for patent infringement and the litigation is still in process.
ABP 501 was recommended for approval for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis (RA), psoriatic arthritis, severe ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe plaque psoriasis, moderate-to-severe hidradenitis suppurativa, noninfectious intermediate, posterior and panuveitis, moderate-to-severe Crohn’s disease, and moderate-to-severe ulcerative colitis. The CHMP also recommended approval for the treatment of certain pediatric inflammatory diseases, including moderate-to-severe Crohn’s disease (ages 6 and older), severe chronic plaque psoriasis (ages 4 and older), enthesitis-related arthritis (ages 6 and older) and polyarticular juvenile idiopathic arthritis (ages 2 and older).
The CHMP’s positive opinion will be reviewed by the European Commission, which is authorized to approve medicines for the EU. The process typically takes approximately 60 days. If approved, ABP 501 will receive a centralized marketing authorization that is valid for the 28 countries in the EU. Norway, Iceland, and Liechtenstein, members of the European Economic Area, will make corresponding decisions on the basis of the EC’s decision.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.